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Abstract
While comorbidity between coronary heart disease (CHD) and depression is evident, it is unclear whether the two diseases
have shared underlying mechanisms. We performed a range of analyses in 367,703 unrelated middle-aged participants of
European ancestry from UK Biobank, a population-based cohort study, to assess whether comorbidity is primarily due to
genetic or environmental factors, and to test whether cardiovascular risk factors and CHD are likely to be causally related to
depression using Mendelian randomization. We showed family history of heart disease was associated with a 20% increase
in depression risk (95% confidence interval [CI] 16–24%, p < 0.0001), but a genetic risk score that is strongly associated
with CHD risk was not associated with depression. An increase of 1 standard deviation in the CHD genetic risk score was
associated with 71% higher CHD risk, but 1% higher depression risk (95% CI 0–3%; p= 0.11). Mendelian randomization
analyses suggested that triglycerides, interleukin-6 (IL-6), and C-reactive protein (CRP) are likely causal risk factors for
depression. The odds ratio for depression per standard deviation increase in genetically-predicted triglycerides was 1.18
(95% CI 1.09–1.27; p= 2 × 10−5); per unit increase in genetically-predicted log-transformed IL-6 was 1.35 (95% CI 1.12–
1.62; p = 0.0012); and per unit increase in genetically-predicted log-transformed CRP was 1.18 (95% CI 1.07–1.29; p=
0.0009). Our analyses suggest that comorbidity between depression and CHD arises largely from shared environmental
factors. IL-6, CRP and triglycerides are likely to be causally linked with depression, so could be targets for treatment and
prevention of depression.
Introduction
Coronary heart disease (CHD) and depression are leading
causes of disability in high-income countries, and are
expected to become so globally by 2030 [1, 2]. There are
three extensively replicated epidemiological observations
regarding CHD and depression. First, these conditions are
highly comorbid [3]. Second, depression is associated with
increased risk of incident CHD [4, 5] and vice versa [6, 7].
Third, depression is a strong predictor of poor prognosis in
people with CHD [4, 8]. However, there are also key
unanswered questions particularly regarding potential
mechanisms underlying this comorbidity. It is unclear
whether the association between CHD and depression
arises from largely shared genetic or environmental factors.
Additionally, while risk factors for CHD are associated
with depression in young [9] and older adults [10, 11], it is
unclear whether these associations are causal. It is possible
that the two illnesses are underpinned by one (or more)
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shared pathophysiologic mechanism, which manifests as
distinct conditions in different organs (i.e., brain and heart).
It was first reported over 50 years ago that around 40% of
patients report depression after acute myocardial infarction
[12]. Features of mild depression are present in up to two-
thirds of patients after acute myocardial infarction [13],
while severe depression is found in around 15% of CHD
patients [14]. This association cannot be explained simply as
a reaction to emotional trauma from a potentially life-
threatening illness. It is clear that the relationship between
CHD and depression has bidirectional aspects. Psychologi-
cal factors including depression were strongly associated
with myocardial infarction in the large, multinational, case-
control INTERHEART study [15]. Meta-analyses of long-
itudinal studies confirm that depression is associated with
incident CHD after controlling for lifestyle and other factors
[4, 5]. Risk factors for CHD such as hyperlipidaemia,
hypertension, diabetes and inflammatory markers are asso-
ciated with risk of depression [9, 10]. These findings indicate
that CHD and depression may have shared mechanisms.
However, common illnesses such as depression and
CHD tend to cluster at population and individual levels
[16], so to what extent this comorbidity is attributable to
shared environmental or shared genetic factors is an out-
standing question. Residual confounding could be an
alternative explanation for previously reported associations
between CHD risk factors and depression. Mendelian ran-
domization is an epidemiological approach that uses genetic
variants as instrumental variables to untangle the problems
of reverse causation (as genetic variants are fixed at con-
ception, hence genetically-predicted levels of risk factors
must precede any event) and unmeasured confounding (as
genetic variants are often specific in their associations with
risk factors) [17]. If genetically-predicted values of a risk
factor are associated with a disease outcome, then it is likely
the association between the risk factor and outcome has a
causal basis [18]. Even if measurement of the genetic var-
iants or the exposure is made after depression diagnosis,
genetic variants predispose individuals to lifelong changes
in exposure levels, hence the exposure still precedes the
outcome. Discovering common causal risk factors is clini-
cally important as they could inform strategies for primary
and secondary prevention. They could also inform further
research into shared mechanisms for these comorbid
conditions.
We have used UK Biobank, a large population-based
cohort study in the United Kingdom, to examine links
between probable lifetime major depression (moderate/severe)
and risk of CHD. Our investigation consisted of three com-
ponents. First, we assessed whether family history of heart
disease was a predictor of depression. Second, we assessed
whether genetic predisposition to CHD risk was a predictor of
depression. Third, we performed Mendelian randomization
analyses for CHD and various CHD risk factors to determine
whether any of these was a causal risk factor for depression.
Subjects and methods
Data sources
The UK Biobank cohort comprises around 500,000 partici-
pants aged 40–69 years at baseline, recruited between 2006
and 2010 in 22 assessment centres throughout the United
Kingdom, and followed up for a variety of health conditions
from their recruitment date until February 17, 2016 or their
date of death [19]. Informed consent was obtained from all
participants. The full dataset includes genome-wide genotyp-
ing of baseline samples from all participants, results of clinical
examinations, assays of biological samples, detailed informa-
tion on self-reported health behaviour, and is supplemented by
linkage with electronic health records such as hospital inpa-
tient data, mortality data and cancer registries. UK Biobank
ethical approval is provided by the UK Biobank research
ethics committee and Human Tissue Authority research tissue
bank. An independent Ethics and Governance Council over-
sees adherence to the Ethics and Governance Framework and
provides advice on the interests of research participants and
the general public in relation to UK Biobank. The current
study was approved by UK Biobank (ref no. 26999).
We restricted our attention to 367,703 unrelated partici-
pants of European ancestry that passed various quality con-
trol tests. European ancestry was defined using self-reported
ethnicity and genomic principal components as described
previously [20]. An initial probable European subset was
defined using genomic principal components. Genetic var-
iants were then dropped from the investigation if they had
low call rate (3 standard deviations away from the mean) or
failed Hardy–Weinberg equilibrium (p-value < 10−6 for
common variants with minor allele frequency > 0.01, p-
value < 10−12 for rare variants with minor allele frequency <
0.01). Individuals were dropped from the investigation if
they had low call rate or excess heterozygosity (3 standard
deviations away from the mean), or mismatch between
genetic and reported sex. Principal components were then re-
calculated on the European ancestry subset, and a further
principal component threshold was applied to exclude non-
Europeans. Finally, we removed related individuals so that
only one person in each family (defined as third-degree
relatives or closer) was included in the analysis.
Outcome
Our primary outcome was self-reported probable lifetime
major depression, either moderate or severe, as previously
used in UK Biobank [21].
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Probable moderate lifetime major depression was
defined using four criteria: (1) answering yes to the question
“Looking back over your life, have you ever had a time
when you were feeling depressed or down for at least a
whole week?” or “Have you ever had a time when you were
uninterested in things or unable to enjoy the things you used
to for at least a whole week?”, (2) answering 2 weeks or
more to the question “How many weeks was the longest
period when you were feeling depressed or down?”, (3)
answering 2 or more to the question “How many periods
have you had when you were feeling depressed or down for
at least a whole week?”, (4) answering yes to the question
“Have you ever seen a general practitioner for nerves,
anxiety, tension or depression?”.
Probable severe lifetime major depression was defined
by the first three criteria and by answering yes to the
question “Have you ever seen a psychiatrist for nerves,
anxiety, tension or depression?”.
We also considered moderate depression and severe
depression separately as secondary outcomes.
Family history of heart disease and depression
Participants were asked about illnesses of their father and
mother, and given a list of conditions to choose from.
Family history of heart disease was defined as the partici-
pant selecting “heart disease” for either their father or
mother. This variable was self-reported, and no validation
was attempted.
Genetic predisposition to coronary heart disease
and depression
Genetic risk scores for CHD were calculated using
1.7 million genetic variants and their associations with CHD
measured in 60,801 cases and 123,504 controls as described
previously [22]. This dataset did not contain any of the UK
Biobank participants. This score has been shown to have
similar predictive ability to a conventional cardiovascular
risk factor score comprising smoking, diabetes, body mass
index (BMI), and hypertension (C-index 0.623 for the
genetic score versus 0.639 for the risk factor score).
Mendelian randomization analyses
Mendelian randomization analyses were conducted for (i)
CHD risk; (ii) various conventional cardiovascular risk
factors: BMI, waist-hip ratio (WHR), systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), and lipids (low-
density lipoprotein [LDL]-cholesterol, high-density lipo-
protein [HDL]-cholesterol, and triglycerides); and (iii)
inflammatory markers: interleukin-1 (IL-1), interleukin-6
(IL-6), fibrinogen, tumour necrosis factor (TNF) alpha,
C-reactive protein (CRP), intercellular adhesion molecule 1
(ICAM1), and P-selectin.
Selection of genetic variants for Mendelian
randomization
For CHD risk, we selected 55 genetic variants previously
associated with CHD risk at a genome-wide level of sig-
nificance in a large meta-analysis of the CARDIo-
GRAMplusC4D consortium [23] (Supplementary Table 1).
Genetic associations with CHD risk were estimated in up to
60,801 CAD cases and 123,504 controls, mostly (~90%) of
European ancestry.
For BMI, we selected 97 genetic variants previously
associated with BMI at a genome-wide level of significance
in a large meta-analysis of the Genetic Investigation of
ANthropometric Traits (GIANT) consortium [24] (Supple-
mentary Table 2). Genetic associations with BMI are esti-
mated in up to 339,224 participants mostly (95%) of
European ancestry. Associations with WHR were obtained
for 48 genetic variants associated with WHR at a genome-
wide significance level from the same participants in the
GIANT consortium [24] (Supplementary Table 3).
For blood pressure, we selected 93 genetic variants pre-
viously associated with either SBP, DBP, or pulse pressure, at
a genome-wide level of significance in a large meta-analysis
of the UK Biobank CardioMetabolic Consortium BP working
group [25] (Supplementary Table 4). Genetic associations
with SBP and DBP are estimated in UK Biobank, in the same
367,703 unrelated participants of European ancestry as the
genetic associations with depression.
For lipids, we selected 185 genetic variants previously
associated with either LDL cholesterol, HDL cholesterol, and
triglycerides, at a genome-wide level of significance in a large
meta-analysis of the Global Lipids Genetic Consortium [26]
(Supplementary Table 5). Genetic associations with lipids are
estimated in up to 188,577 individuals of European ancestry.
For inflammatory markers, we selected genetic variants
in the relevant coding gene region previously shown to be
conditionally associated with the inflammatory biomarker
and only moderately correlated (r2 < 0.6). For interleukin-1,
we selected two variants (rs6743376 and rs1542176) in
the IL1RN gene region. For interleukin-6, we selected
three variants (rs7529229, rs4845371 and rs12740969)
in the IL6R gene region [27]. For fibrinogen, we selected
one variant (rs7439150) in the FGB gene region [28]. For
TNF-alpha, we selected one variant (rs1800629) in the TNF
gene region [29]. For CRP, we selected four variants
(rs1205, rs3093077, rs1130864 and rs1800947) in the CRP
gene region [30]. For ICAM1, we selected five variants
(rs1799969, rs5498, rs1801714, rs281437 and rs11575074)
in the ICAM1 gene region [31]. For P-selectin, we selected
one variant (rs6136) in the SELP gene region [32]. Genetic
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associations with the biomarkers were obtained from the
referenced papers and are listed in Supplementary Table 6.
Statistical analyses
Associations with the depression outcome (moderate/
severe, moderate only, or severe only) were assessed by
logistic regression for family history of heart disease and for
the CHD genetic risk score. Associations of genetic variants
with the outcome were estimated by logistic regression with
adjustment for the first 10 principal components of ancestry.
Analyses were performed in all participants, and in men and
women separately.
For each cardiovascular risk factor and CHD, we per-
formed Mendelian randomization using the inverse-
variance weighted method by weighted regression of the
genetic associations with the outcome on the genetic asso-
ciations with the risk factor [33]. We also performed the
MR-Egger [34] and weighted median [35] methods to
assess the robustness of findings.
For lipids, we conducted analyses separately for each lipid
fraction including all variants associated with that lipid frac-
tion at a genome-wide level of significance (86 variants for
HDL cholesterol, 76 variants for LDL cholesterol, 51 variants
for triglycerides), as well as for all the lipid fractions in a
single analysis model using multivariable Mendelian rando-
mization [36] with all the 185 genetic variants.
For the inflammatory markers, when there are multiple
genetic variants, we report the inverse-variance weighted
estimate with adjustment for correlation between the
variants [33]. The correlation matrix was estimated using
participants from the 1000 Genomes project of European
ancestry. This method combines the genetic associations
with the outcome into a weighted average association
scaled by the genetic association with the biomarker
measure. When there is a single genetic variant, we report
the per allele genetic association with the outcome.
Two-sided p-values are reported throughout, with cor-
rection for multiple testing in the Mendelian randomization
analyses using a p-value of 0.05/15= 0.003, given that 15
risk factors were included in the analysis. Statistical
analyses were conducted using snptest version 2.5.2 or R
version 3.3.2 (“Sincere Pumpkin Patch”). Code for analyses
is available from the authors on request.
Results
Participant characteristics
A summary of participant characteristics is presented
in Table 1. Out of the 367,703 European unrelated parti-
cipants, 14,701 (4.0%) had probable lifetime major
depression (moderate/severe), of whom 8473 (2.3%) were
classed as having moderate depression and 6228 (1.7%) as
severe.
Family history of heart disease and depression
There was evidence for an association between family
history of heart disease and depression (odds ratio [OR]
for moderate/severe depression 1.20, 95% confidence
interval [CI]: 1.16–1.24; moderate only OR 1.26, 95%
CI: 1.21–1.32; severe only OR 1.15, 95% CI: 1.12–1.18;
p < 0.0001 for each outcome). Associations for moderate/
severe depression were similar when restricting the analysis
to men (OR 1.22, 95% CI: 1.16–1.29) and women (OR
1.16, 95% CI: 1.11–1.21).
Table 1 Baseline characteristics
of UK Biobank participants
Characteristic All participants No depression diagnosis Depression diagnosis
Sample size, No. 367,703 353,002 14,701
Male (%) 45.9 46.3 36.7
Age-at-recruitment (years) 57.2 (8.0) 57.2 (8.0) 55.7 (7.8)
Body mass index (kg/m2) 27.4 (4.8) 27.3 (4.7) 27.8 (5.2)
Systolic blood pressure (mmHg) 137.7 (18.6) 137.8 (18.6) 134.1 (17.9)
Diastolic blood pressure (mmHg) 82.0 (10.1) 82.0 (10.1) 81.0 (10.0)
Smoking status (%)
Current 10.3 10.2 13.5
Never 38.8 39 34.1
Ex 50.8 50.7 52.4
Alcohol status (%)
Regular (>3 times per week) 45.4 45.6 41.9
Occasional (<3 times per week) 47.8 47.7 49.3
Never/Ex 6.6 6.5 8.7
Variables are given as percentages or mean (standard deviation)
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Genetic predisposition to coronary heart disease
and depression
A 1 standard deviation increase in the CHD genetic risk
score was associated with a 71% increase in CHD risk [22].
However, there was only weak evidence for an association
between the CHD genetic risk score and depression, and the
magnitude of the association was small: OR per 1 standard
deviation increase in the genetic risk score for major
depression (moderate/severe) 1.01, 95% CI: 1.00–1.03, p=
0.11; moderate only OR 1.03, 95% CI: 1.01–1.05, p=
0.014; severe only OR 0.99, 95% CI: 0.97–1.02, p= 0.66.
Associations for moderate/severe depression were almost
identical for men (OR 1.01, 95% CI: 0.99 or 1.04) and
women (OR 1.01, 95% CI: 0.99, 1.04).
Mendelian randomization analyses
For CHD and the conventional cardiovascular risk factors
(Table 2), only triglycerides showed any evidence for a
causal effect on depression risk, with an odds ratio of 1.18
(95% CI: 1.09–1.27, p= 2 × 10−5) per 1 standard deviation
increase in genetically-predicted triglycerides from the
inverse-variance weighted method (Fig. 1a). Similar results
were observed in the robust methods (Table 2) and for
moderate and severe depression considered separately
(Supplementary Tables 7 and 8).
For the inflammatory biomarkers (Table 3), there was
evidence for causal effects of IL-6 and CRP, with an odds
ratio of 1.35 (95% CI 1.12–1.62; p = 0.0012) per unit
increase in genetically-predicted values of log-transformed
IL-6 (Fig. 1b), and 1.18 (95% CI: 1.07–1.29, p= 0.0009)
per unit increase in genetically-predicted values of log-
transformed CRP (Fig. 1c). The alleles associated with
increased IL-6 levels are also associated with decreased CRP
levels. This provides a discrepancy in the interpretation of
results based on variants in the IL6R and CRP gene regions:
variants in the CRP gene region associated with increased
CRP levels were associated with increased risk of depres-
sion, whereas variants in the IL6R gene region associated
with increased circulating IL-6 levels but decreased IL-6
activity and decreased CRP levels were associated with
increased risk of depression. Further investigation is needed
to understand this discrepancy, which could be linked to
divergent effects of IL-6 classical and trans signalling on
depression risk, and/or CRP-dependent vs CRP-independent
effects of IL-6 on depression risk. Again, similar results
were observed for moderate and severe depression con-
sidered separately (Supplementary Tables 9 and 10). All
other results were compatible with the null, although there
was nominal significance in the association of increased
genetically-predicted IL-1 with increased risk of severe
depression (p= 0.037).
Table 2 Mendelian randomization estimates for conventional
cardiovascular risk factors on probable lifetime major depression
(moderate and severe)
Risk factor Method Odds ratio (95%
confidence interval)
p-value
CHD IVW 1.06 (0.99–1.13) 0.11
MR-Egger 1.06 (0.94–1.18) 0.34
(intercept) 1.00 (0.99–1.01) 0.99
Weighted
median
1.06 (0.97–1.15) 0.28
BMI IVW 1.02 (0.90–1.14) 0.78
MR-Egger 1.26 (0.95–1.67) 0.11
(intercept) 0.99 (0.99–1.00) 0.11
Weighted
median
1.02 (0.87–1.21) 0.79
WHR IVW 1.00 (0.86–1.15) 0.98
MR-Egger 1.07 (0.59–1.92) 0.83
(intercept) 1.00 (0.98–1.01) 0.82
Weighted
median
0.97 (0.78–1.19) 0.75
SBP IVW 0.99 (0.95–1.04) 0.73
MR-Egger 0.96 (0.86–1.07) 0.48
(intercept) 1.01 (0.98–1.03) 0.53
Weighted
median
0.99 (0.93–1.05) 0.68
DBP IVW 1.00 (0.95–1.04) 0.83
MR-Egger 0.98 (0.90–1.07) 0.68
(intercept) 1.00 (0.99–1.01) 0.72
Weighted
median
1.01 (0.95–1.07) 0.79
LDL cholesterol IVW 1.01 (0.94–1.08) 0.80
MR-Egger 1.02 (0.91–1.14) 0.74
(intercept) 1.00 (0.99–1.01) 0.82
Weighted
median
0.98 (0.90–1.08) 0.73
Multivariable 0.99 (0.93–1.05) 0.70
HDL cholesterol IVW 0.97 (0.91–1.03) 0.31
MR-Egger 0.98 (0.88–1.08) 0.69
(intercept) 1.00 (0.99–1.00) 0.71
Weighted
median
1.04 (0.94–1.15) 0.44
Multivariable 1.02 (0.96–1.10) 0.49
Triglycerides IVW 1.18 (1.09–1.27) 2 × 10−5
MR-Egger 1.16 (1.02–1.32) 0.021
(intercept) 1.00 (0.99–1.01) 0.80
Weighted
median
1.18 (1.05–1.32) 0.004
Multivariable 1.17 (1.08–1.28) 0.0003
Mendelian randomization estimates are odds ratios for depression
(95% confidence intervals) for an increase in the risk factor—per unit
increase in the log odds of CHD, per 1 standard deviation increase for
BMI and lipid fractions, and per 1 mmHg increase for systolic and
diastolic blood pressure
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Discussion
We performed several analyses to understand potential shared
mechanisms between CHD and depression. Our analyses
suggest family history of heart disease is strongly associated
with probable lifetime major depression (moderate/severe)
with a 20% relative increase in depression risk associated with
reporting at least one parent dying of heart disease, but a
genetic risk score that predicts CHD risk almost as well as
conventional risk factors was not strongly associated with
depression. This suggests that the comorbidity between the
two conditions arises largely from shared environmental
factors. Further investigation into cardiovascular risk factors
using the Mendelian randomization paradigm elucidated
potential biological pathways contributing to comorbidity. We
provide evidence that, out of all cardiovascular risk factors,
triglycerides and the inflammatory markers IL-6 and CRP are
likely to be causally related to depression.
Fig. 1 Per allele genetic associations with exposure plotted against
associations with risk of probable lifetime major depression, moderate/
severe (log odds ratios) for three exposures: a triglycerides (SD units)
based on 51 genome-wide significant predictors; b interleukin-6 (log-
transformed) based on three genetic variants located in the IL6R gene
region; c C-reactive protein (log-transformed) based on four genetic
variants located in the CRP gene region. The solid line represents the
estimate from the inverse-variance weighted method
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Accumulating evidence supports an important role for low-
grade systemic inflammation indepression [37]. Meta-analyses
of cross-sectional studies confirm that concentrations of
inflammatory markers, such as CRP, IL-6, TNF-alpha, IL-1β,
are elevated in peripheral blood during an acute depressive
episode [38, 39], then tend to subside after recovery but
continue to be elevated in treatment resistant patients [38, 40,
41]. Population-based longitudinal studies including our own
work have reported that higher concentrations of CRP or IL-6
in childhood or adult life are associated with increased risk of
depression or persistent depressive symptoms subsequently at
follow-up [9, 11, 42–44]. Furthermore, a genetic variant in the
IL6R gene (Asp358Ala; rs2228145 A>C), which is known to
dampen down inflammation by impairing IL-6R signalling
[45], was previously reported to be protective for severe
depression [46]. Depressive symptoms and IL-6 share com-
mon genetic predictors [47]. Findings from our Mendelian
randomization analyses add to the existing literature by
showing that reverse causality or residual confounding are
unlikely explanations for previously reported associations
between IL-6, CRP and depression. We provide evidence that
inflammation, particularly the CRP and IL-6/IL-6R pathways,
is causally involved in pathogenesis of depression.
A previous MR study did not find evidence for a causal
association between depression and CRP [48]. Statistical
power could be a reason for the null findings (1128 cases of
depression compared with 14,701 in the current analysis).
Previous Mendelian randomization investigations have
suggested that IL-6 is a causal determinant of CHD risk
[27, 30], but this is not the case for CRP [49, 50]. Therefore,
with regards to shared inflammatory mechanisms under-
pinning the comorbidity between depression and CHD it is
likely that IL-6 is a key driver.
Consistent with our findings, a recent Mendelian rando-
mization study reported potential causal relationships with
depression for LDL cholesterol and for triglycerides [51].
The finding is unlikely to be driven by central obesity,
because BMI or WHR are not causally linked with depres-
sion. Systematic reviews of observational studies suggest that
depression is associated with lower total cholesterol [52], but
the evidence for LDL cholesterol is mixed [53]. A systematic
review of triglyceride concentration in depression compared
with controls is currently lacking. Inflammation leads to
changes in lipid metabolism including decreased HDL cho-
lesterol and increased triglycerides levels [54]. Anti-
inflammatory treatment that inhibits IL-6 also inhibits tri-
glycerides [55]. Elevated IL-6 [9] and triglycerides [56]
levels in childhood are associated with increased risk of
depression in young adulthood. However, lowering of serum
cholesterol in middle-aged subjects by diet, drugs, or both,
leads to a decrease in CHD but an increase in deaths due to
suicide or violence [57]. Mechanisms for this effect are not
understood, but it has been proposed that low membrane
cholesterol could affect serotonergic neurotransmission by
decreasing the number of serotonin receptors [57]. Further
work is needed to understand the relationships between lipid
alterations and depression.
How inflammation causes depression and CHD has been
studied extensively; see reviews [58, 59]. In brief, direct
effects of peripheral inflammation relevant for cardiovas-
cular risk include the development of atherosclerotic lesions
in the arterial tree, and effects on endothelial reactivity and
myocardial function [59]. Peripheral inflammation also
influences the central nervous system. Brain responses to
inflammation involve neural systems for motivational and
homoeostatic control and are expressed through depressed
mood state and changes in autonomic cardiovascular reg-
ulation [60]. As for depression, extensive animal and human
studies have demonstrated that peripheral immune activa-
tion leads to changes in mood and behaviour by increasing
turnover of serotonin, oxidative stress, activation of the
hypothalamic-pituitary-adrenal (HPA) axis, and by reducing
synaptic plasticity [58].
A strong association of depression with family history of
heart disease, but not with a genetic risk score for CHD,
suggests that the comorbidity between depression and CVD
arises largely from shared environmental factors. Although
we did not observe an association between the genetic risk
score for CHD and depression, it is likely that there is some
contribution from shared genetic predictors, as a genetic
correlation between CHD and depression has previously
been reported. However, the magnitude of this correlation
Table 3 Mendelian
randomization results for
inflammatory biomarkers on
probable lifetime major
depression (moderate and
severe)
Biomarker Scale OR (95% CI) p-value
IL-1 Per 1 SD increase in IL-1Ra 1.06 (0.98–1.14) 0.17
IL-6 Per unit increase in log-transformed IL-6 1.35 (1.12–1.62) 0.0012
Fibrinogen Per unit increase in log-transformed fibrinogen 0.96 (0.42–2.20) 0.92
TNF-alpha Per TFN expression increasing allele 0.99 (0.96–1.02) 0.68
CRP Per 1 unit increase in log-transformed CRP 1.18 (1.07–1.29) 0.0009
ICAM-1 Per 20 ng/dL increase in sICAM-1 1.01 (0.99–1.04) 0.22
P-selectin Per P-selectin concentration increasing allele 0.97 (0.95–1.00) 0.16
Mendelian randomization estimates are odds ratios for depression (95% confidence intervals) either per unit
increase in the risk factor or per allele as indicated
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was low [61, 62]. According to a large Swedish twin study,
acute environmental factors play a large role in depression-
CHD comorbidity in men, whereas in women chronic fac-
tors, which are in part genetic, are more important [62].
However, we did not observe any sex-difference in the
observational associations of depression with CHD family
history or genetic risk. Nearly two-thirds of depression
cases in our study were female. The observational asso-
ciation between family history of CHD and depression may
also be influenced by dynastic effects. For example, indi-
viduals with family history of heart disease will have been
exposed to risk factors for heart disease (and potentially also
for depression) through their family environment, i.e. con-
founding by shared environment.
With regards to shared environmental factors, the
depression–CHD comorbidity could be linked with early-
life factors influencing inflammatory regulation, such as
impaired foetal development or childhood maltreatment.
This idea is consistent with the common-cause or foetal
programming hypothesis by David Barker [63]. Low birth
weight, a catchall marker of suboptimal foetal development,
and childhood maltreatment are associated with increased
levels of circulating inflammatory markers [64, 65],
depression [66] and CHD [67] in adulthood.
Limitations of the work include the quality of the
depression outcome. A working group of the UK Biobank
study used self-reported data to create variables for probable
recurrent major depression (moderate/severe) named
according to Diagnostic and Statistical Manual for Mental
Disorders (DSM) terminology. We use the term probable
lifetime major depression to describe the same variable as
we could not be certain whether criteria for ‘recurrent’ were
fulfilled. Nevertheless, based on these criteria the prevalence
of probable lifetime major depression (moderate/severe) in
our sample was 4.0%, which is unlikely to be an over-
estimate. Lifetime prevalence of major depression is around
10–20% according to general population studies [68]. Mis-
classification of cases as controls introduces a bias towards
the null, so the associations between genetic variants and
depression observed in our analysis are likely to be con-
servative, and may well under-estimate the true impact of the
risk factors on disease risk. Our investigation focused on
CHD and cardiovascular risk factors as causes of depression,
but the reverse analysis could also be performed. As future
work, the association between a genetic risk score for
depression and CHD risk could be investigated.
A better understanding of causal risk factors for depres-
sion could inform novel strategies for treatment and pre-
vention. Lifestyle modifications targeting ‘inflammogenic’
risk factors such as physical inactivity, obesity, smoking and
alcohol use could improve risks for both CHD and depres-
sion. Inflammation is associated with antidepressant resis-
tance [41, 69], so anti-inflammatory drugs may be helpful
for patients with depression who show evidence of immune
activation. Anti-cytokine drugs that inhibit IL-6 or TNF-
alpha signalling improve depressive symptoms in patients
with chronic inflammatory illness, independently of
improvement in physical illness [70]. Randomized trials
testing the efficacy of novel anti-inflammatory drugs in
patients with depression are currently ongoing.
In summary, we provide evidence that the comorbidity
between depression and CHD largely arises from shared
environmental factors. Certain risk factors for CHD, spe-
cifically IL-6, CRP and triglycerides, are likely to be cau-
sally linked with depression, so these could be targets for
treatment and prevention of the illness.
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